Tempus AI (NASDAQ:TEM) Stock Price Down 9.5% – Should You Sell?

Shares of Tempus AI, Inc. (NASDAQ:TEM) were down 9.5% during trading on Tuesday . The company traded as low as $45.25 and last traded at $45.15. Approximately 4,582,990 shares changed hands during trading, a decline of 8% from the average daily volume of 4,957,588 shares. The stock had previously closed at $49.87.

Analysts Set New Price Targets

TEM has been the topic of several research analyst reports. Wolfe Research lowered shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Morgan Stanley increased their price target on shares of Tempus AI from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Thursday, March 6th. Loop Capital reduced their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Guggenheim reiterated a “buy” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Finally, Piper Sandler reduced their price target on Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Tempus AI presently has a consensus rating of “Moderate Buy” and an average price target of $61.18.

Tempus AI Stock Performance

The stock’s 50-day moving average price is $55.51 and its 200-day moving average price is $51.60. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Insider Activity at Tempus AI

In other Tempus AI news, Director Jennifer A. Doudna sold 1,320 shares of Tempus AI stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $90.00, for a total value of $118,800.00. Following the completion of the sale, the director now directly owns 36,011 shares in the company, valued at approximately $3,240,990. The trade was a 3.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Eric P. Lefkofsky sold 187,655 shares of the stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $37.54, for a total value of $7,044,568.70. Following the transaction, the chief executive officer now owns 9,557,283 shares in the company, valued at $358,780,403.82. The trade was a 1.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,749,469 shares of company stock worth $322,529,733 over the last quarter.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently bought and sold shares of TEM. GSA Capital Partners LLP bought a new position in shares of Tempus AI during the 3rd quarter worth about $306,000. First Horizon Advisors Inc. bought a new position in Tempus AI in the third quarter worth approximately $30,000. The Manufacturers Life Insurance Company grew its stake in Tempus AI by 10.2% in the third quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock valued at $1,686,000 after acquiring an additional 2,765 shares during the period. Captrust Financial Advisors bought a new stake in shares of Tempus AI during the third quarter valued at approximately $2,726,000. Finally, NEA Management Company LLC raised its position in shares of Tempus AI by 17.8% during the third quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock worth $304,846,000 after purchasing an additional 813,169 shares during the period. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.